MARKET

FATE

FATE

Fate Therapeutic
NASDAQ
3.760
+0.170
+4.74%
After Hours: 3.768 +0.008 +0.22% 19:59 06/21 EDT
OPEN
3.650
PREV CLOSE
3.590
HIGH
3.810
LOW
3.610
VOLUME
8.30M
TURNOVER
0
52 WEEK HIGH
8.83
52 WEEK LOW
1.630
MARKET CAP
428.01M
P/E (TTM)
-1.9618
1D
5D
1M
3M
1Y
5Y
Piper Sandler Upgrades Fate Therapeutics (FATE)
NASDAQ · 4d ago
Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
Fate Therapeutics is a clinical-stage biopharmaceutical company. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. 9 analysts have set 12-month price targets for Fate Therapeutic. The average price target for the company is $6.11.
Benzinga · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Broadcom, Xponential Fitness, Northfield Bancorp
Wall Street's main indexes edged lower on Monday. The Dow Jones Industrial Average was up 0.02% at 38,598.09. Autodesk, Xponential Fitness and Northfield Bancorp were among the top gainers. Broadcom was up 3.8% after the company announced a new CEO.
Reuters · 4d ago
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Goldman Sachs analyst Susan Maklari upgraded the rating for Toll Brothers, Inc. From Sell to Neutral. Keurig Dr Pepper Inc. Shares fell 0.1% to close at $34.04 on Friday. UBS analyst Michael Lasser upgraded Best Buy Co. From Neutral to Buy.
Benzinga · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Autodesk, Aaron's Company
Futures tracking Wall Street's main indexes were mixed in muted trading on Monday. Investors awaited fresh economic data and comments from Federal Reserve officials for more clarity on monetary policy. Autodesk, Aaron's Company and BHP Group were among the top stocks on the day.
Reuters · 4d ago
BUZZ-Piper Sandler raises Fate to 'overweight' on disease treatment progress
Piper Sandler raises Fate to 'overweight' on disease treatment progress. Shares of biopharma company Fate Therapeutics gain 10.25% to $3.98 premarket. Brokerage cites progress in transition from development of cancer treatment to autoimmune disease therapies.
Reuters · 4d ago
Weekly Report: what happened at FATE last week (0610-0614)?
Weekly Report · 4d ago
Fate Therapeutics Price Target Raised to $6.00/Share From $4.00 by Piper Sandler
Dow Jones · 4d ago
More
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.

Webull offers Fate Therapeutics Inc stock information, including NASDAQ: FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.